HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Suppression of Tumor Growth and Metastases by Targeted Intervention in Urokinase Activity with Cyclic Peptides.

Abstract
Urokinase-type plasminogen activator (uPA) is a diagnostic marker for breast and prostate cancers recommended by American Society for Clinical Oncology and German Breast Cancer Society. Inhibition of uPA was proposed as an efficient strategy for cancer treatments. In this study, we report peptide-based uPA inhibitors with high potency and specificity comparable to monoclonal antibodies. We revealed the binding and inhibitory mechanisms by combining crystallography, molecular dynamic simulation, and other biophysical and biochemical approaches. Besides, we showed that our peptides efficiently inhibited the invasion of cancer cells via intervening with the processes of the degradation of extracellular matrices. Furthermore, our peptides significantly suppressed the tumor growth and the cancer metastases in tumor-bearing mice. This study demonstrates that these uPA peptides are highly potent anticancer agents and reveals the mechanistic insights of these uPA inhibitors, which can be useful for developing other serine protease inhibitors.
AuthorsDong Wang, Yongshuai Yang, Longguang Jiang, Yu Wang, Jinyu Li, Peter A Andreasen, Zhuo Chen, Mingdong Huang, Peng Xu
JournalJournal of medicinal chemistry (J Med Chem) Vol. 62 Issue 4 Pg. 2172-2183 (02 28 2019) ISSN: 1520-4804 [Electronic] United States
PMID30707839 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Enzyme Inhibitors
  • Peptides, Cyclic
  • Urokinase-Type Plasminogen Activator
Topics
  • Animals
  • Antineoplastic Agents (therapeutic use)
  • Carcinoma (drug therapy, pathology)
  • Cell Line, Tumor
  • Colon (pathology)
  • Colonic Neoplasms (drug therapy, pathology)
  • Enzyme Inhibitors (therapeutic use)
  • Lung Neoplasms (secondary)
  • Male
  • Mice, Inbred BALB C
  • Molecular Dynamics Simulation
  • Neoplasm Invasiveness
  • Peptides, Cyclic (therapeutic use)
  • Urokinase-Type Plasminogen Activator (antagonists & inhibitors)
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: